Diabetes mellitus and closed-loop insulin delivery

Biotechnology and Genetic Engineering Reviews

Volumn 17, Issue , 2000, Pages 455-496

  Adams, Gary ^a   Clark, Jan ^b   Sahota, Tarsem ^b   Tanna, Sangeeta ^b   Taylor, M Joan ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSED-LOOP INSULIN DELIVERIES; DIABETES MELLITUS;

INSULIN;

CLINICAL FEATURE; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG METABOLISM; HUMAN; PANCREAS ISLET CELL; REVIEW;

EID: 0034485631     PISSN: 02648725     EISSN: None     Source Type: Journal    
DOI: 10.1080/02648725.2000.10648002     Document Type: Review

References (198)

1. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
2. Glucose sensitive membranes for controlled delivery of insulin: Insulin transport studies
3. Theoretical and experimental studies of glucose sensitive membranes
4. An artificial endocrine pancreas
5. Development and evaluation of the biodegradeable polyphosphazenes
6. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
7. Multicentre trial of a programmable implantable insulin pump in type 1 diabetes
8. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial
9. Blood pressure control in type 2 diabetes - What does the United Kingdom prospective siabetes study (UKPDS) tell us?
10. Intensive insulin therapy compared with conventional insulin therapy does not reduce depressive symptoms in parents of children with type 1 diabetes
11. Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: Dissociation of a protein-ligand complex
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
13. Suitability of aqueous dispersions of dextran and concanavalin A for glucose sensing in different variants of the affinity sensor
14. Kinetics of dissolution of concanavalin A dextran sols in response to glucose measured by surface plasmon resonance
15. The internal secretion of the pancreas
16. Glycosylated insulins
17. The molecular structure of concanavalin A
18. The covalent and three-dimensional structure of concanavalin A. III. Structure of the monomer and its interaction with metals and saccharides
19. The molecular structure of concanavalin A
20. Complications of type 2 diabetes mellitus: A brief overview
21. The effects of pancreas transplantation on the glomerular structure of renal-allografts in patients with insulin-dependent diabetes
22. Towards understanding fibrillation
23. The U.K. prospective diabetes study. A review
24. Protein delivery with infusion pumps
25. Comments on metabolic needs for glucose and the role of gluconeogenesis
26. A glucose controlled insulin delivery system: Semisynthetic insulin bound to lectin
27. Glycosylated insulin complexed to concanavalin A. Biochemical basis for a closed-loop insulin delivery system
28. Insulins
29. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus
30. Solution structures of the R6 human insulin hexamer
31. Novel methods of insulin delivery: An update
32. Transdermal iontophoretic delivery of therapeutic peptides, proteins, insulin
33. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice
34. Implications of the United Kingdom prospective diabetes study
35. Polymeric matrices
36. Optimization of release from magnetically controlled polymeric drug release devices
37. Polymer based drug delivery: Magnetically modulated and bioerodible systems
38. Semantics of insulin
39. New classification and diagnostic criteria for diabetes mellitus
40. Performance of subcutaneously implanted glucose sensors: A review
41. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro
42. Bioencapsulation within synthetic polymers (Part 1): Sol-gel encapsulated biologicals
43. Experience with the Biostator for diagnosis and assisted surgery of 21 insulinomas
44. Lipoprotein concentrations and carotid atherosclerosis by diabetes status - Results from the insulin resistance atherosclerosis study
45. Protein-carbohydrate interaction Part (I) the interaction of polysaccharides with concanavalin A
46. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes
47. Method for the quantification of alginate in microcapsules
48. Feedback controlled drug delivery
49. A crossover comparison of continuous insulin infusion (csii) and conventional injection (cit) therapy of type-i diabetes
50. Dextran hydrogels for the controlled release of proteins
51. Interaction between polymeric drug delivery systems and biological systems: Barriers and opportunities
52. Glucose-responsive gel from phenylborate polymer and poly(vinyl alcohol): Prompt response at physiological pH through the interaction of borate with amine group in the gel
53. Pharmacokinetic considerations of new insulin formulations and routes of administration
54. Insulin lispro
55. Intensive insulin therapy in clinical practice
56. Swelling behaviour of glucose sensitive membranes
57. A bioresponsive membrane for insulin delivery
58. Chronic rejection in pancreas transplant recipients: A multivariate analysis of risk factors
59. Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset Type I (insulin-dependent) diabetes mellitus
60. Simulation of a complex protein structural-change
61. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression
62. Dextrans and pullulans: Industrially significant alpha-D-glucans
63. Self regulating insulin delivery systems i - Synthesis and characterisation of glycosylated insulin
64. Self-regulating insulin delivery systems iii - In-vivo studies
65. Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue
66. Novel glucose-sensitive polymers and hydrogels based on phenylborate-containing polymers
67. Totally synthetic polymer gels responding to external glucose concentration: Their preparation and application to on-off regulation of insulin release
68. On-off regulation of insulin-release by totally synthetic polymer gels responding to external glucose concentration
69. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic neuropathy
70. Recent developments in insulin delivery techniques - Current status and future potential
71. Application of a binary polymer system in drug release rate modulation.1. Characterization of release mechanism
72. Application of binary polymer system in drug release rate modulation.2. Influence of formulation variables and hydrodynamic conditions on release kinetics
73. Self-regulated insulin delivery - Artificial pancreas
74. Self-regulating insulin delivery system - A chemical approach
75. Development of glucose-triggered ph-sensitive liposomes for a potential insulin delivery
76. A novel drug delivery system utilising a glucose responsive complex formation between poly(vinyl alcohol) and poly(N-vinyl-2-pyrrolidone) with a pendent phenylboronic acid moiety
77. Prediction and prevention of type 1 diabetes
78. Postprandial blood-glucose response to exercise in type - I diabetes - Comparison between pump and injection therapy
79. Glucose sensitive membranes containing glucose oxidase. Activity, swelling and permeability studies
80. Diabetes mellitus: Current classification based on cause and sharpened blood glucose limits for diagnosis
81. Insulin lispro, a new insulin analog
82. Sur la formation desilots de Langerhans dans le pancreas
83. Dextran prodrugs-structure and stability in relation to therapeutic activity
84. Immunogenicity of long term intraperitoneal insulin administration with implantable programmable pump. Metabolic consequences
85. Use of implantable insulin pumps: The evadiac position
86. Synthesis of sol-gel phase reversible hydrogels sensitive to glucose
87. United Kingdom prospective diabetes study (UKPDS): What now or so what?
88. Comparative stereochemical analysis of glucose-binding proteins for rational design of glucose-specific agents
89. Solute transport analysis in pH-responsive, complexing hydrogels of poly(methacrylic acid-g-ethylene glycol)
90. Molecular analysis of interpolymer complexation in graft copolymer networks
91. Oral delivery of insulin using pH-responsive complexation gels
92. Sugar binding polymers showing high anomeric and epimeric discrimination obtained by noncovalent molecular imprinting
93. Acute complications associated with insulin infusion pump therapy - Report of experience with 161 patients
94. Transdermal delivery of human insulin to albino rabbits using electrical-current
95. Current status of the glucose sensor
96. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus
97. CD11a expression and soluble ICAM-1 levels in peripheral blood in high-risk and overt type 1 diabetes subjects
98. Formation of poly(glucosyloxyethyl methacrylate): Concanavalin A complex and its glucose-sensitivity
99. The role of modelling studies in the development of future controlled release devices
100. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
101. Gel-sol phase-reversible hydrogels sensitive to glucose
102. Characterization of glucose dependent gel-sol phase transition of the polymeric glucose-concanavalin A hydrogel system
103. Characterization of protein release through glucose-sensitive hydrogel membranes
104. Glycation of proteins and phospholipids: Maillard reaction in vivo
105. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited
106. Concanavalin a microspheres for a self-regulating insulin delivery system
107. Synthesis and characterization of soluble concanavalin-a oligomer
108. Controlled drug delivery
109. Hypoglycemia counterregulation is intact in successful, long-term pancreas transplant recipients
110. Hypoglycemia counterregulatory responses in successful pancreas transplant recipients of 11-19 years duration
111. Enzymatic and methylation analysis of dextrans and (1-]3)-alpha-D-glucans
112. Poly(ethylene glycol)-containing hydrogels in drug delivery
113. Transdermal iontophoresis. Part II: Peptide and protein delivery
114. Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: Independence of surfactant action from multimer dissociation
115. The biodegradeability of polyester blends
116. Dynamic behavior of glucose oxidase-containing microparticles of poly(ethylene glycol)-grafted cationic hydrogels in an environment of changing pH
117. Glucose-sensitivity of glucose oxidase-containing cationic copolymer hydrogels having poly(ethylene glycol) grafts
118. Preparation and dynamic response of cationic copolymer hydrogels containing glucose oxidase
119. Bioartificial organs. 1. Silica gel encapsulated pancreatic islets for the treatment of diabetes mellitus
120. Minimizing the aggregation of neutral insulin solutions
121. Mechanisms of stabilization of the insulin hexamer through allosteric
122. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes-mellitus
123. Involvement of cell-cell interactions in the pathogenesis of diabetic retinopathy
124. Localization of glycated proteins in the glomeruli of patients with diabetic nephropathy
125. Chemistry of insulin
126. Future developments in insulin delivery systems
127. Implantable insulin pump vs multiple dose insulin for non-insulin-dependent diabetes mellitus: A randomised clinical trial
128. Novel forms of insulin delivery
129. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial)
130. Long-term compliance of intensified insulin therapy
131. Implications of the UKPDS study for general practice care of type 2 diabetes
132. Novel poly(ethylene glycol)-grafted, cationic hydrogels: Preparation, characterization and diffusive properties
133. Compositional effects on network structure of highly crosslinked copolymers of PEG-containing multiacrylates with-acrylic acid
134. Management of diabetes with glucose sensors and implantable insulin pumps - From the dream of the 60s to the realities of the 90s
135. Amine containing phenylboronic acid gel for glucose-responsive insulin release under physiological pH
136. Amine effect on phenylboronic acid compiler with glucose under physiological pH in aqueous solution
137. T-cell insulitis found in anti-GAD65+ diabetes with residual beta-cell function. A case report
138. Specificity of metal ion interaction with concanavalin A
139. Facilitated transdermal transport of insulin
140. Modelling of self-regulating oscillatory drug delivery
141. In vivo imaging of insulitis in autoimmune diabetes
142. Structural stability in the 4-zinc human insulin hexamer
143. Long-term reversal of diabetes by the injection of immunoprotected islets
144. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus
145. Potential novel methods for insulin administration. 2. Self-regulating internal-drug delivery systems
146. The identification of the hemagglutinin of the Jack Bean with concanavalin A
147. Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus
148. A self regulating delivery system using high molecular weight solutes in glucose sensitive gel membranes
149. Glucose-responsive gels based on dextran covalently coupled with lectin to control insulin delivery
150. Characterization of model solute and insulin delivery across covalently modified lectin-polysaccharide gels sensitive to glucose
151. Insulin delivery governed by lectin-glycogen gels sensitive to glucose
152. Insulin delivery governed by covalently modified lectin-glycogen gels sensitive to glucose
153. A self regulated delivery system using unmodified solutes in glucose sensitive gel membranes
154. A novel self regulated delivery system using unmodified solutes in glucose sensitive gel membranes
155. Insulin delivery using a novel glucose-sensitive formulation
156. The delivery of insulin from aqueous and non-aqueous reservoirs governed by a glucose sensitive gel membrane
157. Insulin delivery system based on an affinity chemical valve
158. Future prevention and treatment of diabetic neuropathy
159. Recent approaches in insulin delivery
160. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: Role of the polyol pathway
161. Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus
162. Pharmacologic therapy for type 2 diabetes mellitus
163. Iontophoretic devices for drug delivery
164. Benefits and risks of meticulous control of diabetes
165. Phase-reversible hydrogels based on acrylamide-N-(2-D- glucose)acrylamide copolymers
166. Chemical modification of polymers with physiologically active species using water-soluble carbodiimides
167. Degradation and release behaviour of dextran based hydrogels
168. Formation of advanced glycation end (AGE) products in diabetes: Prevention by pyruvate and alpha-keto glutarate
169. Diabetes mellitus nach pankreasextipation
170. Conformation of concanavalin-a and its fragments in aqueous-solution and organic solvent-water mixtures
171. Insulin lispro: A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus
172. New criteria for the detection, diagnosis, and classification of diabetes mellitus
173. Structural and morphological characterization of ultralente insulin crystals by atomic force microscopy: Evidence of hydrophobically driven assembly